Back to Search
Start Over
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
- Source :
- GlobeNewswire. May 9, 2024
- Publication Year :
- 2024
-
Abstract
- - Apnimed to Present Rationale and Design of LunAIRo Phase 3 Study for AD109 at the ATS 2024 International Conference - Topline Phase 3 Data Expected in Mid-2025 CAMBRIDGE, Mass., [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.793200802